Figure 3From: Price regulation, new entry, and information shock on pharmaceutical market in Taiwan: a nationwide data-based study from 2001 to 2004 Market share of NSAIDs products, quarterly, 2001-2004. The market share (cost) of NASIDs products had been largely substituted by celecoxib and rofecoxib up to 26.92% and 19.68%, respectively, in a three-year period.Back to article page